An interventional study of Transcranial photobiomodulation therapy and Transcranial pseudo-photobiomodulation in Older Adults, Surgery and Transcranial Photobiomodulation, sponsored by Peking University First Hospital. Recruiting at 1 site in China. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by Peking University First Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Emergence Delirium by Peking University First Hospital — 5 open to participants now, 5 under way, none of them phase 3. Emergence Delirium · Peking University First Hospital.
Among the 11 studies in Emergence Delirium by Peking University First Hospital, this one is the 7th largest by planned enrollment, is one of 2 that started in 2026, is one of 4 with no phase, and was the 11th registered.
753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.
Browse Emergence Delirium studies →5 of the 11 studies in Emergence Delirium by Peking University First Hospital are open now, in 1 country. Recruiting first, the newest first:
Peking University First Hospital · Sites in China
Ages 1–6
Peking University First Hospital · Sites in China
Ages 65+
Peking University First Hospital · Sites in China
Ages 50–90
Peking University First Hospital · Sites in China
Ages 65–90 · Healthy volunteers
By country, each count listing its studies:
Of the 141 Emergence Delirium studies recruiting now, 78 (55%) set no upper age limit and 43 (30%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 130 is close to the median of 120 across 467 interventional studies indexed under Emergence Delirium.
Median enrollment 248 across the 11 interventional studies. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Peking University First Hospital is the lead sponsor of 393 studies on the registry; 188 are open to participants now.
3 of the studies in Emergence Delirium by Peking University First Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07523334Peking University First HospitalImpact of Esketamine on Delayed Neurocognitive Recovery in Older Patients | 2026-12 |
| NCT07046364Peking University First HospitalRemimazolam and Emergence Delirium in Pediatrics | 2027-01-01 |
| NCT07736092Peking University First HospitalPerioperative Transcranial Photobiomodulation and Delayed Neurocognitive Recovery in Older Patients | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 11 studies in Emergence Delirium by Peking University First Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Delayed neurocognitive recovery is a common neurocognitive complication in older patients after surgery, especially those with preoperative neurocognitive decline. Transcranial photobiomodulation therapy is a novel neuromodulation technique using transcranial low-power light to modulate brain biological functions. This technique has been used to treat various neurological or psychiatric conditions, including ischemic stroke, traumatic brain injury, and major depression. This study is designed to explore whether using transcranial photobiomodulation therapy during the perioperative period can reduce the incidence of delayed neurocognitive recovery in older patients with pre-existing neurocognitive impairment.
Along with the aging population, the number of older adults undergoing surgery is increasing. Neurocognitive complications (such as delirium and delayed neurocognitive recovery) are common in older patients after surgery, especially those with pre-existing neurocognitive decline. Occurrence of neurocognitive complications are associated with wose early and long-term outcomes.
Transcranial photobiomodulation therapy is a novel neuromodulation technique using transcranial low-power light to modulate brain biological functions. Study results in healthy volunteers showed favorable effects on neurocognitive functions. This technique has been safely used to treat various neurological or psychiatric conditions, including ischemic stroke, traumatic brain injury, and major depression. Transcranial photobiomodulation therapy may reduce postopeative neurocognitive complications in high risk patients but evience is limited.
This study is designed to explore whether using transcranial photobiomodulation therapy during the perioperative period can reduce neurocognitive complications in older patients with pre-existing neurocognitive impairment. The primary endpoint is delayed neurocognitive recovery; secondary endpoints include postoperative delirium.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A transcranial photobiomodulation therapy device employing medium-intensity LED near-infrared light will be applied to the forehead of participants. Treatments will be done twice daily on the day before surgery and on the first and second days after surgery, and once on the day of surgery, with at least 8 hours between any two interventions.
Device: Transcranial photobiomodulation therapy
A transcranial photobiomodulation therapy device employing extremely low-intensity LED near-infrared light will be applied to the forehead of participants. Treatments will be done twice daily on the day before surgery and on the first and second days after surgery, and once on the day of surgery, with at least 8 hours between any two interventions.
Device: Transcranial pseudo-photobiomodulation
A transcranial photobiomodulation therapy device employing medium-intensity LED near-infrared light will be applied to the foreheads of participants. Treatments will be done twice daily on the day before surgery and on the first and second days after surgery, and once on the day of surgery, with at least 8 hours between any two treatments. Each intervention will last 10 minutes. The investigators conducting the bedside intervention will monitor the safety of participants during the interventions.
A transcranial photobiomodulation therapy device employing extremely low-intensity LED near-infrared light will be applied to the foreheads of participants. Treatments will be done twice daily on the day before surgery and on the first and second days after surgery, and once on the day of surgery, with at least 8 hours between any two treatments. Each intervention will last 10 minutes. The investigators conducting the bedside intervention will monitor the safety of participants during the interventions.
Incidence of delayed neurocognitive recovery
Cognitive function will be assessed at baseline and at 4 days after surgery (or before hospital discharge if ealier) using the Montreal Cognitive Assessment (MoCA; scores range from 0 to 30, with higher scores indicating better cognitive function). Delayed neurocognitive decline (dNCR) is defined as: a \|Z\| value of decline in MoCA score ≥1.96. Z value = \[(change from baseline in MoCA score in a surgical patient - mean change from baseline in MoCA score in the non-surgical group)\] / (standard deviation of change from baseline in MoCA score in the non-surgical group).
Time frame: On the 4th day after surgery or before discharge if earlier
Incidence of postoperative delirium
Delirium will be assessed twice daily (8-10 am and 6-8 pm) using the 3-Dimensional Confusion Assessment Method (3D-CAM) for patients without intubation or the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) for patients with intubation.
Time frame: Up to 3 days after surgery
Incidence of postoperative neurocognitive disorder
Cognitive function will be assessed at baseline and at 30 days after surgery using the Montreal Cognitive Assessment (MoCA; scores range from 0 to 30, with higher scores indicating better cognitive function). Postoperative neurocognitive disorder (pNCD) is defined as: a \|Z\| value of decline in MoCA score ≥1.96. Z value = \[(change from baseline in MoCA score in a surgical patient - mean change from baseline in MoCA score in the nonsurgical group)\] / (standard deviation of change from baseline in MoCA score in the non-surgical group).
Time frame: At 30 days after surgery
Early postoperative pain intensity
Pain intensity will be assessed twice daily (8-10 am and 6-8 pm) both at rest and with movement (coughing or turning over) using an 11-point Numeric Rating Scale (NRS; scores range from 0 to 10 where 0=no pain and 10=the worst pain).
Time frame: Up to 3 days after surgery
Early postoperative subjective sleep quality
Subjective sleep quality will be assessed once daily (8-10 am) using an 11-point Numeric Rating Scale (NRS; scores range from 0 to 10 where 0=the best sleep and 10=the worst sleep.
Time frame: Up to nights after surgery3
Hospital stay after surgery
From the day of surgery until the day of hospital discharge.
Time frame: Up to 30 days after surgery
Postopeative complications within 30 days
Postoperative complications are defined as new-onset conditions that are deemed harmful and required therapeutic intervention, i.e., grade II or above on the Clavien-Dindo classification.
Time frame: Up to 30 days after surgery
Plan to share: No
Started Aug 2026 (actual). Primary completion is estimated for Jul 2027, 11 months after the start.
Of 186 non-industry interventional studies with no phase under Emergence Delirium, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 11 months is below that.
Counting every sponsor, half of 186 studies reached it within 19 months; a quarter within 7 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University First Hospital →